Dec 7, 2016 - Jane Trepel,3 Seth Steinberg,4 Pamela Harris,5. Raffit Hassan,1 Patrick Loehrer Sr2 1Thoracic and. Gastrointestinal Oncology Branch, Center ...
ABSTRACTS
ORAL ABSTRACT SESSION WEDNESDAY, DECEMBER 7, 2016 OA18.01 Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort Clémence Basse,1 Sébastien Thureau,1 Suzanna Bota,2 Eric Dansin,3 Pascal Alexandre Thomas,4 Eric Pichon,5 Hervé Léna,6 Carole Massabeau,7 Christelle Clément-Duchêne,8 Gilbert Massard,9 Virginie Westeel,10 François Thillays,11 Xavier Quantin,12 Youssef Oulkhouir,13 Serge Danhier,14 Delphine Lerouge,14 Luc Thiberville,2 Benjamin Besse,15 Nicolas Girard16 1 Cancer Center, Rouen/France, 2University Hospital, Rouen/France, 3Cancer Center, Lille/France, 4University Hospital, Marseille/France, 5University Hospital, Tours/ France, 6University Hospital, Rennes/France, 7University Cancer Center, Toulouse/France, 8Cancer Center, Nancy/ France, 9University Hospital, Strasbourg/France, 10 University Hospital, Besançon/France, 11Cancer Center, Nantes/France, 12University Hospital, Montpellier/France, 13 University Hospital, Caen/France, 14Cancer Center, Caen/France, 15Department of Cancer Medicine, Gustave Roussy, Villejuif/France, 16Thoracic Oncology, Hospices Civils de Lyon, Lyon/France Background: Thymic Epithelial Tumors (TET) are rare intrathoracic malignancies, for which surgery represents the mainstay of the treatment strategy. Current practice for postoperative mediastinal radiotherapy is highly variable, and there is paucity of prospective, multicenter evidence. RYTHMIC is the nationwide network for TET in France, established in 2012. Whether postoperative radiotherapy (PORT) should be delivered was the most frequent question raised at the RYTHMIC multidisciplinary tumor board (MTB) over the past 3 years, accounting for 494 (35%) of a total of 1401 questions. Methods: All consecutive patients for whom postoperative adjuvant radiotherapy was discussed at the RYTHMIC MTB from 2012 to 2015 were identified from the RYTHMIC prospective database. Results: 285 patients were identified, 274 (52% men, 48% women) of whom fulfilled inclusion criteria. Average age at time of TET diagnostic was 60 years. TET histology was thymoma in 243 (89%) cases - including
type A in 11% of cases, type AB in 28%, type B1 in 17%, type B2 in 29%, and type B3 in 14% -, and thymic carcinoma in 31 (11%) of cases. Complete resection was achieved in 81% of patients. Masaoka-Koga stage was stage I in 29% of cases, IIA in 21%, IIB in 21%, III in 18%, and IVA/B in 11%. Decision of the MTB was consistent with guidelines in 221 (92%) assessable cases. Clinical situations for which PORT was indicated in accordance with guidelines (84 cases) were thymoma/R1 resection (30 patients), thymoma/R0 resection/stage III (22 patients), thymoma/R0 resection/ stage IIB/type B2/B3 histology (11 patients), thymic carcinoma/R1 resection (6 patients), thymic carcinoma/ R0 resection (13 patients), thymoma/R0 resection/stage IIA/type B3 histology (2 patients). Inconsistencies between decision of the MTB and guidelines e 20 (8%) cases - consisted of abstention related to poor general condition (10 patients), carcinoid histology (2 patients), and discordance in staging (1 patient), and of delivery of radiotherapy related to peroperative tumor fragmentation (2 patients); for 5 patients who received PORT, a clear explanation for inconsistency with guidelines was not found, but those cases actually corresponded to those in a “grey zone” of guidelines. MTB decision for PORT was actually implemented for 99 (85%) of patients; most frequent reason for not delivering radiotherapy was prolonged delay since surgery. Conclusion: Our data provide with a unique insight into the decision-making process for PORT in thymic epithelial tumors, highlighting the need for a systematic discussion at an expert MTB, while stressing the value of current available guidelines. Keywords: Radiotherapy, Adjuvant treatment, Thymoma, Thymic carcinoma
OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma Arun Rajan,1 Chul Kim,1 Udayan Guha,1 Eva Szabo,1 Arlene Berman,1 Linda Sciuto,1 A. John Spittler,2 Jane Trepel,3 Seth Steinberg,4 Pamela Harris,5 Raffit Hassan,1 Patrick Loehrer Sr2 1Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda/MD/United States of America, 2Division of Hematology/Oncology, Indiana
Journal of Thoracic Oncology
Vol. 12 No. 1S: S313-S341
